Clinical Nephrology, Volume 105 (2026) - May (352 - 359)

Fibronectin glomerulopathy caused by genetic FN1 mutation: A case report and literature review

Bairu Shi1, 2, Yang Xia1, 2, Kejia Li1, 2, Long Jin1, 2, Xian Sun1, 2, Hui Yu3, 4
1 Department of Nephrology, The First People’s Hospital of Jiashan, Jiaxing City, Zhejiang Province, 2 Department of Nephrology, Jiashan Branch of the Second Affiliated Hospital of Medical College Zhejiang University, Jiaxing, 3 Department of Orthopedics Surgery, The First People’s Hospital of Jiashan, Jiaxing City, Zhejiang Province, and 4 Department of Orthopedics Surgery, Jiashan Branch of the Second Affiliated Hospital of Medical College Zhejiang University, Jiaxing, China

   

 

DOI 10.5414/CN111907

Abstract

Background: Fibronectin glomerulopathy (FGP), also known as fibronectin deposition glomerulopathy (GFND), is a rare hereditary autosomal dominant glomerular disease. Its clinical manifestations are proteinuria, hematuria, hypertension, and hyperkalemic distal renal tubular acidosis, which often progresses slowly to end-stage renal disease.
Case description: We report a 21-year-old woman with fibronectin glomerulopathy who underwent renal puncture at the age of 10. The pathology was considered to be thrombotic microangiopathy, and it was not treated regularly. This time, renal puncture was performed again due to proteinuria combined with elevated serum creatinine. Light microscopy showed severe mesangial matrix hyperplasia of glomeruli with dense deposition and foam cell aggregation in capillary loops. Fibrinogen immunostaining was positive. Electron microscope showed severe hyperplasia of mesangial matrix, and a large amount of electron-dense matter deposited in mesangial area. Perfect genetic testing suggested that the FN1 gene was heterozygous for NM_212482.4 (c.2918A>G), that is, Y973C mutation. Therefore, she was diagnosed with fibronectin glomerulopathy and was given sacubitril valsartan sodium tablets 200 mg b.i.d. orally.
Conclusion: We report a case of a patient with fibronectin glomerulopathy and review the literature of this disease. The disease often has insidious onset, and fibronectin deposition is a typical pathological change that can result. The disease slowly progresses to end-stage renal disease. At present, there is no specific treatment. It is advocated to use reninangiotensin-aldosterone system blockers to strictly control blood pressure and proteinuria, and the overall prognosis is poor. Genetic testing techniques may be helpful in early diagnosis of the disease.

Author Details

Authors

Departments

  • 1 Department of Nephrology, The First People’s Hospital of Jiashan, Jiaxing City, Zhejiang Province,
  • 2 Department of Nephrology, Jiashan Branch of the Second Affiliated Hospital of Medical College Zhejiang University, Jiaxing,
  • 3 Department of Orthopedics Surgery, The First People’s Hospital of Jiashan, Jiaxing City, Zhejiang Province, and
  • 4 Department of Orthopedics Surgery, Jiashan Branch of the Second Affiliated Hospital of Medical College Zhejiang University, Jiaxing, China

Address

Dr. Hui Yu
Department of Orthopedics Surgery
The First People’s Hospital of Jiashan
or
Department of Orthopedics Surgery
Jiashan Branch of the Second Affiliated
Hospital of Medical College Zhejiang University
1218 South Sports Road
Jiaxing City, PR China
Email: [email protected]

Citation

Bairu Shi, Yang Xia, Kejia Li, Long Jin, Xian Sun, Hui Yu.Fibronectin glomerulopathy caused by genetic FN1 mutation: A case report and literature review
. Clin Nephrol. 2026; 105: 352-359. doi: 10.5414/CN111907. Pubmed: https://pubmed.ncbi.nlm.nih.gov/41642109/; PMID: 41642109.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart